UM Ventures Celebrates Tokai Pharmaceuticals' Positive Interim Clinical Results for Galeterone, a Drug Candidate Discovered by UM Baltimore Researchers
Wednesday, February 12, 2014
Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer and other hormonally driven cancers, announced on January 29, 2014, positive interim results from the Phase 2 ARMOR2 study with reformulated galeterone (TOK-001), which demonstrated promising reductions in prostate-specific androgen (PSA) levels, a marker of prostate cancer growth in patients with castration-resistant prostate cancer (CRPC). To date, galeterone has been well tolerated.
Angela Brodie, Ph.D. and Vincent Njar, Ph.D., researchers at the University of Maryland, Baltimore, discovered galeterone, which was licensed to Tokai.